EZH2 and B-cell chronic lymphocytic leukemia: We found that combined inhibition of EZH2 activity and BcR signaling had synergistic antitumor effects while EZH2 inhibitors exhibited ex vivo efficacy in CLL cases unresponsive to signaling inhibitors (44).